Treasurer of the State of North Carolina Sells 10,837 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Treasurer of the State of North Carolina cut its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 172,089 shares of the biopharmaceutical company's stock after selling 10,837 shares during the quarter. Treasurer of the State of North Carolina's holdings in Royalty Pharma were worth $4,390,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the stock. APG Asset Management US Inc. acquired a new position in Royalty Pharma in the 4th quarter worth about $201,000. Raymond James Financial Inc. acquired a new position in Royalty Pharma in the fourth quarter worth approximately $19,990,000. APG Asset Management N.V. raised its position in Royalty Pharma by 4.8% during the fourth quarter. APG Asset Management N.V. now owns 382,906 shares of the biopharmaceutical company's stock valued at $9,433,000 after acquiring an additional 17,406 shares in the last quarter. Invesco Ltd. lifted its stake in Royalty Pharma by 33.2% in the fourth quarter. Invesco Ltd. now owns 957,893 shares of the biopharmaceutical company's stock valued at $24,436,000 after acquiring an additional 238,508 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd grew its position in Royalty Pharma by 36.7% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 4,890 shares of the biopharmaceutical company's stock worth $125,000 after acquiring an additional 1,312 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

NASDAQ:RPRX traded down $0.11 during mid-day trading on Monday, hitting $32.49. 247,531 shares of the company's stock traded hands, compared to its average volume of 3,247,332. The firm has a market capitalization of $18.73 billion, a price-to-earnings ratio of 22.46, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The firm has a 50 day moving average of $32.57 and a two-hundred day moving average of $29.29. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of recent research reports. TD Cowen upgraded shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma currently has an average rating of "Buy" and an average target price of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.